Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28834673 | 0.90 | LMNA (0.57) | MTNR1ATDP1CDYLMEN1KMT2A | |
| SCHEMBL11566791 | 0.89 | MTNR1A (0.54) | MTNR1ATDP1CDYLMEN1KMT2A | |
| SCHEMBL11567919 | 0.88 | MTNR1A (0.52) | MTNR1ATDP1CDYLMEN1KMT2A | |
| SCHEMBL20917770 | 0.85 | TDP1 (0.51) | MTNR1ATDP1CDYLCHRM5CHRM1 | |
| SCHEMBL6989892 | 0.83 | CDYL (0.53) | MTNR1ATDP1CDYLMEN1KMT2A | |
| SCHEMBL6421718 | 0.83 | TDP1 (0.50) | MTNR1ATDP1CDYLMEN1KMT2A | |
| SCHEMBL7018412 | 0.83 | MTNR1A (0.56) | MTNR1A | |
| SCHEMBL1998527 | 0.83 | MEN1 (0.59) | MTNR1ATDP1MEN1KMT2APARP10 | |
| SCHEMBL28342504 | 0.83 | LMNA (0.44) | MTNR1ACDYLMEN1KMT2APARP10 | |
| SCHEMBL21596423 | 0.82 | MEN1 (0.56) | MTNR1ATDP1CDYLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175006-B2 | Compositions and methods for cyclofructans as separation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-11-03 | — | — | US | claimed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-6972294-B1 | Compounds, their preparation and use | NOVO NORDISK, A/S (DK) | 2005-12-06 | — | — | US | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1266900-A1 | Carbamates of rapamycin | Wyeth (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-1171414-A1 | COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2002-01-16 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| EP-1123279-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000063153-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000023425-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| US-5928515-A | LIQUID CHROMATOGRAPHY TO STEREOSPECIFICALLY ADSORB ENANTIOMORPH ONTO POLYSACCHARIDE CARBAMATE AND SUBSEQUENT DESORPTION WITH LOW MOLECULAR WEIGHT ALIPHATIC ALCOHOL | UOP LLC (US) | 1999-07-27 | — | — | US | disclosed |
| US-5532402-A | Process for producing optically active hydroxyalkylphosphonates | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-07-02 | — | — | US | disclosed |
| US-5411967-A | Antiinflammatory, immunosuppressant, antitumor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0593227-A1 | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-20 | — | — | EP | disclosed |
| US-5302584-A | Immunosuppressants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-12 | — | — | US | disclosed |
| US-5039801-A | Refluxing in alcoholic solution | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1991-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | MTNR1A 3582/4885TDP1 1385/4885CDYL 655/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | MTNR1A 339/4885TDP1 4505/4885CDYL 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.